If with TLD-1433, next Ph. 1b = Cervical or Head&NeckIn fact, cervical and head & neck cancer indications have been identified as using TLD-1433. Not Rutherrin.
GBM, lung and esophagus will all be using Rutherrin.
And cervical and throat, a bit like a bladder and contrary to brain, could have something in common; they are "cavities" at first glance, where you could "instill" the PDC. _____________________
September 5, 2017
- About 12,820 new cases of invasive cervical cancer will be diagnosed.
-
- About 4,210 women will die from cervical cancer
In research conducted by Pavel Kaspler, Ph.D., Research Scientist, Theralase, under the direction of Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase, it has been demonstrated that cervical cancer cells (ME180) were up to 96% destroyed, at an extremely low dose of TLD-1433 (0.1 micromolar), when activated by green laser light (530 nm, 90 J/cm2)
The dark toxicity (TLD-1433, but no laser light applied) was virtually negligible, supporting a high safety margin in the destruction of cervical cancer cells.
Dr. Kaspler stated that, “The research data collected strongly suggests that TLD-1433 would be effective in the destruction of cervical cancer with high safety margins. I look forward to continuing my research in this promising new cancer indication.”
Dr. Mandel stated that, “I am very pleased that TLD-1433 continues to make strides forward in the destruction of oncology targets, demonstrating high efficacy in the destruction of numerous cancers preclinically. Clinically, in the first 3 patients treated at the Maximum Recommended Starting Dose, we have demonstrated safety and tolerability, pharmacokinetics (the movement and exit of the drug within tissue) and efficacy, when evaluated at 90 days post treatment for Non-Muscle Invasive Bladder Cancer. We have strong preclinical data supporting the use of Rutherrin® (TLD-1433 + transferrin) in the destruction of glioblastoma brain cancer and lung cancer and now TLD-1433 on its own in the destruction of cervical cancer.”
_________________
September 19, 2017 In research conducted by Pavel Kaspler, Ph.D., Research Scientist, Theralase, under the direction of Arkady Mandel, MD, Ph.D., D.Sc., Chief Scientific Officer, Theralase, it has been demonstrated that a human pharyngeal carcinoma cell line (FaDu) was 98% destroyed, at an extremely low dose of TLD-1433 (0.2 micromolar), when activated by green laser light (530 nm, 90 J/cm2) and 98% destroyed, at a low dose of TLD-1433 (25 micromolar), when activated by red laser light (625 nm, 90 J/cm2).
The ability to activate TLD-1433 at both green and red laser wavelengths allows the PDC to be activated at various tissue depths corresponding to the progression of the disease.
The dark toxicity (TLD-1433, but no laser light applied) was virtually negligible, when activated by green laser light, and low, when activated by red laser light, supporting a high safety margin in the destruction of human pharyngeal carcinoma cells.
Dr. Mandel stated that, “TLD-1433 continues to advance in the destruction of new oncology targets, demonstrating high efficacy in the destruction of numerous cancers preclinically. We have strong preclinical data supporting the use of Rutherrin® (TLD-1433 + transferrin) in the destruction of glioblastoma brain cancer and lung cancer and now TLD-1433 on its own in the destruction of cervical and pharyngeal cancer.”
The overall 5-year survival rate for people with oral or oropharyngeal cancer is 64%.
It is estimated that 9,700 deaths (7,000 men and 2,700 women) from these 2 diseases will occur this year.